Intensity Therapeutics (INTS) Retained Earnings (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Retained Earnings came in at -$80.8 million in Q1 2026, down 15.26% YoY from -$95.4 million in Q1 2025, and down 3.08% on a QoQ basis from -$78.4 million in Q4 2025.
Intensity Therapeutics (INTS) Retained Earnings (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Retained Earnings data on file, last reported at -$80.8 million in Q1 2026.
- Quarterly Retained Earnings fell 15.26% year-over-year to -$80.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$80.8 million (down 15.26% YoY) and the FY2025 annual result came in at -$78.4 million, down 17.38% from the prior year.
- Retained Earnings fell to -$80.8 million in Q1 2026, from -$78.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $64.8 million in Q1 2024 to a low of -$80.8 million in Q1 2026.
- A 5-year average of -$36.1 million and a median of -$63.6 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2025 — Retained Earnings plunged 208.11% — and 2026, when it declined 15.26%.
- Tracing INTS's Retained Earnings over 5 years: stood at -$38.7 million in 2022, then tumbled by 30.69% to -$50.5 million in 2023, then tumbled by 32.2% to -$66.8 million in 2024, then decreased by 17.38% to -$78.4 million in 2025, then declined by 3.08% to -$80.8 million in 2026.
- The last three Retained Earnings figures came in at -$80.8 million (Q1 2026), -$78.4 million (Q4 2025), and -$75.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 93.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 93.04 Mn |
| Mar 31, 2026 | -80.80 Mn |
| Dec 31, 2025 | -78.39 Mn |
| Sep 30, 2025 | -75.34 Mn |
| Jun 30, 2025 | -72.70 Mn |
| Mar 31, 2025 | -70.10 Mn |
| Dec 31, 2024 | -66.78 Mn |
| Sep 30, 2024 | -63.60 Mn |
| Jun 30, 2024 | -60.10 Mn |
| Mar 31, 2024 | 64.84 Mn |
| Dec 31, 2023 | -50.52 Mn |
| Sep 30, 2023 | 63.25 Mn |
| Jun 30, 2023 | 60.15 Mn |
| Dec 31, 2022 | -38.65 Mn |